Literature DB >> 9137079

Charge-based binding of complement component C1q to the Alzheimer amyloid beta-peptide.

S Webster1, B Bonnell, J Rogers.   

Abstract

Activation of the classical pathway in Alzheimer's disease derives from the binding of the first protein, subcomponent C1q, to the amyloid beta-peptide (A beta). Analysis of the binding of C1q to A beta by competitive enzyme-linked immunosorbent assay shows that A beta fragments 1-16 and 1-28 but not 12-28 and 17-42 are capable of inhibiting the A beta/C1q interaction, implicating the A beta 1-11 region as the C1q binding site. Binding is also shown to be inhibited by conditions of high ionic strength, suggesting that charged side chains in the A beta 1-11 region are critical to the A beta/c1q interaction. Ultrastructural evidence of binding is provided by platinum replica electron microscopy. Along with a previous demonstration of the 14-26 region of the C1q A chain as the A beta binding site, these findings suggest that attractions between a negative charge cluster in A beta 1-11 and a positive charge cluster in C1qA14-26 mediate the binding of A beta and C1q.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9137079      PMCID: PMC1858209     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  30 in total

1.  Complement activation in amyloid plaques in Alzheimer's dementia.

Authors:  P Eikelenboom; C E Hack; J M Rozemuller; F C Stam
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1989

Review 2.  The classical complement pathway: activation and regulation of the first complement component.

Authors:  N R Cooper
Journal:  Adv Immunol       Date:  1985       Impact factor: 3.543

3.  Cerebral amyloid plaques in Alzheimer's disease but not in scrapie-affected mice are closely associated with a local inflammatory process.

Authors:  P Eikelenboom; J M Rozemuller; G Kraal; F C Stam; P A McBride; M E Bruce; H Fraser
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1991

4.  Relative efficacies of amyloid beta peptide (A beta) binding proteins in A beta aggregation.

Authors:  S Webster; J Rogers
Journal:  J Neurosci Res       Date:  1996-10-01       Impact factor: 4.164

5.  Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study.

Authors:  P Eikelenboom; F C Stam
Journal:  Acta Neuropathol       Date:  1982       Impact factor: 17.088

6.  Aggregation and secondary structure of synthetic amyloid beta A4 peptides of Alzheimer's disease.

Authors:  C Hilbich; B Kisters-Woike; J Reed; C L Masters; K Beyreuther
Journal:  J Mol Biol       Date:  1991-03-05       Impact factor: 5.469

7.  Immune system response in Alzheimer's disease.

Authors:  P L McGeer; H Akiyama; S Itagaki; E G McGeer
Journal:  Can J Neurol Sci       Date:  1989-11       Impact factor: 2.104

8.  Molecular determinants of amyloid deposition in Alzheimer's disease: conformational studies of synthetic beta-protein fragments.

Authors:  K Halverson; P E Fraser; D A Kirschner; P T Lansbury
Journal:  Biochemistry       Date:  1990-03-20       Impact factor: 3.162

9.  In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity.

Authors:  C J Pike; A J Walencewicz; C G Glabe; C W Cotman
Journal:  Brain Res       Date:  1991-11-01       Impact factor: 3.252

10.  Brain microglia constitutively express beta-2 integrins.

Authors:  H Akiyama; P L McGeer
Journal:  J Neuroimmunol       Date:  1990-11       Impact factor: 3.478

View more
  17 in total

Review 1.  Local neuroinflammation and the progression of Alzheimer's disease.

Authors:  Patrick L McGeer; Edith G McGeer
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

2.  Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient.

Authors:  Alex E Roher; Chera L Maarouf; Ian D Daugs; Tyler A Kokjohn; Jesse M Hunter; Marwan N Sabbagh; Thomas G Beach
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

Review 3.  Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective.

Authors:  Javed Ahmad; Sohail Akhter; Md Rizwanullah; Mohammad Ahmed Khan; Lucie Pigeon; Richard T Addo; Nigel H Greig; Patrick Midoux; Chantal Pichon; Mohammad Amjad Kamal
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

4.  Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease.

Authors:  S E Stoltzner; T J Grenfell; C Mori; K E Wisniewski; T M Wisniewski; D J Selkoe; C A Lemere
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

5.  Nanodisc-Forming Scaffold Protein Promoted Retardation of Amyloid-Beta Aggregation.

Authors:  Bikash Ranjan Sahoo; Takuya Genjo; Sarah J Cox; Andrea K Stoddard; G M Anantharamaiah; Carol Fierke; Ayyalusamy Ramamoorthy
Journal:  J Mol Biol       Date:  2018-08-28       Impact factor: 5.469

Review 6.  Focal inflammation in the brain: role in Alzheimer's disease.

Authors:  N R Cooper; B M Bradt; S O'Barr; J X Yu
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

7.  Islet amyloid polypeptide triggers limited complement activation and binds complement inhibitor C4b-binding protein, which enhances fibril formation.

Authors:  Jonatan Sjölander; Gunilla T Westermark; Erik Renström; Anna M Blom
Journal:  J Biol Chem       Date:  2012-02-13       Impact factor: 5.157

8.  Increased fibrillar beta-amyloid in response to human clq injections into hippocampus and cortex of APP+PS1 transgenic mice.

Authors:  Kristal W Boyett; Giovanni DiCarlo; Paul T Jantzen; Jennifer Jackson; Charlotte O'Leary; Donna Wilcock; Dave Morgan; Marcia N Gordon
Journal:  Neurochem Res       Date:  2003-01       Impact factor: 3.996

9.  CLAC: a novel Alzheimer amyloid plaque component derived from a transmembrane precursor, CLAC-P/collagen type XXV.

Authors:  Tadafumi Hashimoto; Tomoko Wakabayashi; Atsushi Watanabe; Hisatomo Kowa; Ritsuko Hosoda; Atsushi Nakamura; Ichiro Kanazawa; Takao Arai; Koji Takio; David M A Mann; Takeshi Iwatsubo
Journal:  EMBO J       Date:  2002-04-02       Impact factor: 11.598

10.  Reaction of complement factors varies with prion strains in vitro and in vivo.

Authors:  Rie Hasebe; Gregory J Raymond; Motohiro Horiuchi; Byron Caughey
Journal:  Virology       Date:  2012-01-03       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.